

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CAMA-1

RRID:CVCL_1115

Type: Cell Line

Proper Citation

RRID:CVCL_1115

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1115

Proper Citation: RRID:CVCL_1115

Description: Cell line CAMA-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: [PMID:833871](#), [PMID:924690](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:10862037](#), [PMID:11343771](#), [PMID:12353263](#), [PMID:12661003](#), [PMID:12800145](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAMA-1

Synonyms: Cama-1, CAMA1, CAMA

Cross References: BTO:BTO_0005022, CLO:CLO_0002194, EFO:EFO_0001100, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-21, BioGRID_ORCS_Cell_line:588, BioSample:SAMN03472698, BioSample:SAMN10987851, cancercellines:CVCL_1115, CancerTools:161925, Cell_Model_Passport:SIDM00920, ChEMBL-Cells:ChEMBL3308719, ChEMBL-Targets:ChEMBL1075416, Cosmic:687468, Cosmic:871153, Cosmic:904354, Cosmic:946382, Cosmic:997930, Cosmic:1000130, Cosmic:1046925, Cosmic:1047717, Cosmic:1136349, Cosmic:1287905, Cosmic:1289386, Cosmic:1603195, Cosmic:1995361, Cosmic:2165018, Cosmic:2750520, Cosmic-CLP:946382, DepMap:ACH-000783, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:946382, GEO:GSM344344, GEO:GSM344394, GEO:GSM378143, GEO:GSM421864, GEO:GSM783930, GEO:GSM827295, GEO:GSM843488, GEO:GSM843489, GEO:GSM847248, GEO:GSM847458, GEO:GSM886917, GEO:GSM887983, GEO:GSM984230, GEO:GSM1008894, GEO:GSM1053694, GEO:GSM1172856, GEO:GSM1172948, GEO:GSM1215264, GEO:GSM1238119, GEO:GSM1374437, GEO:GSM1661977, GEO:GSM1669660, IARC_TP53:18372, LiGeA:CCLE_527, LINCS_HMS:50131, LINCS_LDP:LCL-1466, Lonza:1251, PharmacDB:CAMA1_181_2019, PRIDE:PXD002486, PRIDE:PXD030304, Progenetix:CVCL_1115, PubChem_Cell_line:CVCL_1115, SLKBase:3405, Wikidata:Q54808432

ID: CVCL_1115

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260905T174514+0000

Ratings and Alerts

No rating or validation information has been found for CAMA-1.

No alerts have been found for CAMA-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell chemical biology, 33(6), 785.

Sottnik JL, et al. (2026) Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling. bioRxiv : the preprint server for biology.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. *Cancer research*, 86(1), 116.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Bartkowiak K, et al. (2025) Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients. *Scientific reports*, 15(1), 3913.

Medina EF, et al. (2025) System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells. *Cell reports. Medicine*, 6(11), 102425.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Chen W, et al. (2025) Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. *Cancer discovery*.

Armand J, et al. (2025) Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. *eLife*, 14.

Boettcher L, et al. (2025) Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer. *Breast cancer research : BCR*, 27(1), 137.

Minati R, et al. (2025) CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling. *Cell reports*, 44(12), 116676.

Albrecht J, et al. (2024) Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. *Molecular oncology*.

Yu J, et al. (2024) Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell*, 187(17), 4713.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. *Breast cancer research : BCR*, 26(1), 192.

Toader D, et al. (2023) Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. *Molecular cancer therapeutics*, 22(9), 999.

Jamal K, et al. (2022) Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. *Cancer research communications*, 2(10), 1244.

Aka Y, et al. (2021) Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. *The international journal of biochemistry & cell biology*, 137, 106028.

Zhu C, et al. (2021) Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1. *Cell reports*, 34(7), 108749.